A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

Differentiated thyroid cancer (DTC) responds to VEGF receptor inhibitors. VEGF signals through RAS/RAF/MEK signaling. We evaluated the safety and efficacy of the VEGF receptor inhibitor pazopanib and MEK inhibitor trametinib in advanced solid tumors and DTC. Patients with advanced solid tumors were...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2019-09, Vol.25 (18), p.5475-5484
Hauptverfasser:	Kurzrock, Razelle, Ball, Douglas W, Zahurak, Marianna L, Nelkin, Barry D, Subbiah, Vivek, Ahmed, Shabina, O'Connor, Ashley, Karunsena, Enusha, Parkinson, Rose M, Bishop, Justin A, Ha, Yoonji, Sharma, Rajni, Gocke, Christopher D, Zinner, Ralph, Rudek, Michelle A, Sherman, Steven I, Azad, Nilofer S
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!